-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read and refer to "Youyoung Good Medical Voice" Shanghai-Fujian-Gan Station wonderful case sharing is coming!
Case 1: First-line maintenance therapy, fruquintinib is worth exploring The case is provided by Zhongshan Hospital affiliated to Fudan University: Professor Cui Yuehong; Case sharer: Dr.
Xu Xiaojing Case Summary:
Liu Queling Case Summary:
Case 3: Intestines for a long time The case was tutored by Renji Hospital affiliated to Shanghai Jiao Tong University: Professor Xiao Xiuying; Case Sharer: Dr.
Han Ting Case Summary:
Case 4: Surviving the life of young patients The case was provided by Fujian Provincial Cancer Hospital as a supervisor: Professor Li Hui; Case Sharer: Dr.
Tim Song Case Summary:
Case 5: Fruquintinib monotherapy to help "chemotherapy" leave The case was provided by the Affiliated East Hospital of Tongji University: Professor Gao Yong; Case Sharer: Dr.
Hai Yanan Case Summary:
Case 6: Young patients are more suitable for fruquintinib combined with PD-1 inhibitorsThe case is provided by the First Affiliated Hospital of Xiamen University: Professor Li Jiayi; Case sharer: Dr.
He Qi Case Summary:
On September 4, 2022, the Chinese Society of Clinical Oncology (CSCO) Colorectal Cancer Special Committee and Huang Pharma jointly held the "YOUNG Good Medical Voice | Presentation on the whole process management of advanced colorectal cancer"——Shanghai-Fujian-Gan Station was grandly opened
online.
This conference invited a number of well-known domestic experts and young doctors to share clinical practice experience and answer questions around the hot topics of precision diagnosis and treatment of advanced colorectal cancer through case sharing
.
At the beginning of the conference, Professor Yang Jianwei of Fujian Cancer Hospital, Chairman of the Conference, and Professor Li Qi, First People's Hospital Affiliated to Shanghai Jiao Tong University, delivered speeches at the conference, saying that "Excellent YOUNG Good Medical Voice" not only provides a stage for young doctors to show themselves, but also a way
for doctors to collect typical cases and difficult cases.
I hope that all young doctors can fully show their style, learn from each other, improve language expression and slide making ability, and help improve the diagnosis and treatment of
advanced colorectal cancer.
I hope to create more opportunities for face-to-face communication in the future, and wish the conference a complete success
.
Figure 1 Professor Yang Jianwei, Chairman of the Conference, Fujian Cancer Hospital, delivered a speech
Figure 2 Professor Li Qi, Chairman of the Conference, First People's Hospital Affiliated to Shanghai Jiao Tong University, delivered a speech
Fierce competition, wonderful presentation - six excellent diagnosis and treatment cases to share
Subsequently, the meeting entered the case sharing session, which was co-chaired
by Professor Li Qi of the First People's Hospital of Shanghai Jiao Tong University, Professor Liu Zhenhua of Fujian Provincial Hospital, Professor Chen Zhiyu of Fudan University Cancer Hospital and Professor Peng Junjie of Fudan University Cancer Hospital 。 Professor Yang Sheng from Union Medical College Hospital of Fujian Medical University, Professor Ma Lijun from Tongren Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Professor Ye Jianming from the First Affiliated Hospital of Gannan Medical College, Professor Yang Zhiyong from Chongming Branch of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Professor Guo Yuling from the First Affiliated Hospital of Nanchang University, and Professor Guo Yuanbiao from Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine served as the judging panels
.
Case 1: First-line maintenance therapy, fruquintinib is worth exploring The case is provided by Zhongshan Hospital affiliated to Fudan University: Professor Cui Yuehong; Case sharer: Dr.
Xu Xiaojing Case Summary:
Case 1, a 60-year-old patient, was diagnosed with sigmoid colon adenocarcinoma and complete mismatch repair function (pMMR)
in September 2020.
After the MDT discussion, the first-line treatment of the patient was treated with bevacizumab combined with the FOLFOXIRI regimen for 6 cycles, during which the liver was interventional once to evaluate partial response (PR), at which time the tumor burden was still large and the adverse reactions were obvious
.
The first-line maintenance phase
began in February 2021.
At this time, patients were enrolled in the FRONT study and randomized to fruquintinib (5 mg) treatment
.
After 4 cycles of medication, the efficacy was evaluated as stable with reduced disease (SD), and after 4 cycles, the primary lesion
was surgically removed.
The second-line PD-1 inhibitor combined with bevacizumab progressed intrahepatic lesions during the epidemic, and the third-line PD-1 inhibitor combined with fruquintinib is still being treated
.
Case 2, a 59-year-old man with no history of other diseases, was diagnosed with rectal-sigmoid junction carcinoma in April 2019, with concurrent radical resection and postoperative pathology of moderately differentiated adenocarcinoma (pT3N0M0), who underwent 8 cycles of adjuvant chemotherapy
.
In November 2020, he relapsed and was treated with capecitabine with radiotherapy
.
Multiple metastatic lesions reappeared in both lungs in March 2021, and first-line treatment began in March, using the FOLFIRI protocol for 8 cycles, during which SD
was assessed.
In the maintenance treatment stage, the FRONT study was randomized to the fruquintinib treatment group, the dose was 2 mg in the first cycle, 5 mg in the second to twelfth cycle, and the drug was repeated every two months, all SD, and the current patient continued treatment for more than 1 year, and the progression-free survival (PFS) was > 12 months
.
The above two cases suggest that the first-line treatment of fruquintinib in the FRONT study has brought excellent PFS benefits to patients with advanced CRC, and the adverse effects are mild
.
More large-scale controlled studies are expected to confirm this in order to bring clinical benefit
to more patients.
Figure 3 Dr.
Xu Xiaojing shared a case
Liu Queling Case Summary:
The patient, a 45-year-old female who was admitted to the hospital for the first time in December 2014, showed a diagnosis of rectal cancer (T3aN+M0) on pathological examination, followed by neoadjuvant chemoradiotherapy, surgical resection 3 months later, postoperative adjuvant chemotherapy, and no recurrence
at regular follow-up.
In August 2018, the tumor recurred and metastasized, untreated for 1 year, multiple metastases in both lungs in July 2019, and was admitted to the hospital in August, and the first-line treatment after MDT discussion was treated with cetuximab combined with FOLFIRI for 12 cycles, and the efficacy was evaluated as CR.
In October 2020, the tumor progressed, and the patient received fruquintinib (4mg) treatment, and the efficacy was evaluated as disease progression (PD)
after 3 cycles.
In January 2021, the patient received fruquintinib (4mg) in combination with a PD-1 inhibitor, and the patient has been PFS for more than 18 months
.
This case suggests that, as demonstrated in some early clinical studies, fruquintinib combined with immunotherapy may bring longer survival benefits
to patients with advanced colorectal cancer.
Figure 4 Dr.
Liu Queling sharing a case
Case 3: Intestines for a long time The case was tutored by Renji Hospital affiliated to Shanghai Jiao Tong University: Professor Xiao Xiuying; Case Sharer: Dr.
Han Ting Case Summary:
The patient is a 64-year-old woman diagnosed with ascending colon adenocarcinoma in July 2014 with concurrent liver metastases (3 lesions) and potentially resectable
potential.
In July 2014, he underwent surgical treatment of ascending colon cancer, and the postoperative stage was stage IV (pT3N1M1), RAS wild type, and adjuvant chemotherapy was performed after surgery, and the efficacy was evaluated as SD.
In January 2015, liver metastases were resected, followed by 2 cycles of chemotherapy, and the efficacy of SD was evaluated
.
During regular follow-up until July 2018, the left lung nodule was found, and the postoperative pathology suggested that the left upper lung was primary lung cancer (T1N0M0) and the left lower lung was intestinal adenocarcinoma metastasis, and the postoperative follow-up observation
.
In November 2018, after 9 cycles of irinotecan combined with cetuximab after tumor recurrence, cetuximab monotherapy maintenance therapy
was performed.
In August 2019, the disease progressed, and the patient was treated with regorafenib, but due to intolerance of adverse reactions, he was subsequently switched to fruquintinib (3 mg) treatment, and the lesion was reduced
during treatment.
In June 2021, the efficacy was evaluated as increased SD, which had not yet reached PD.
At this time, the family still wanted to be actively treated, so fruquintinib (3mg) combined with PD-1 inhibitor treatment, during which the efficacy was evaluated as SD, and PFS has been used for more than 3 years
.
This case demonstrates the potential value of small molecule TKI sequential immunotherapy such as fruquintinib in the era of "chemotherapy-de-chemotherapy", which can bring good therapeutic benefits
to patients.
Figure 5 Dr.
Han Ting sharing a case
Case 4: Surviving the life of young patients The case was provided by Fujian Provincial Cancer Hospital as a supervisor: Professor Li Hui; Case Sharer: Dr.
Tim Song Case Summary:
The patient is a 37-year-old male who was diagnosed with colon cancer (cT4bN+M0) in 2020, and underwent surgical treatment after 3 cycles of neoadjuvant therapy and 4 cycles of postoperative adjuvant therapy, and the efficacy was evaluated as PD.
In November 2020, the patient received 6 cycles of treatment with FOLFIRINOX combined with bevacizumab, but the disease progressed
due to the epidemic.
In subsequent treatment, patients continued to receive FOLFIRINOX combined with bevacizumab, and the efficacy of 3 cycles was evaluated as PD
.
After progression, fruquintinib (5mg) combined with PD-1 inhibitors was used, and the efficacy was evaluated as PR, and the patient is currently benefiting continuously
.
This case suggests that fruquintinib in combination with immunotherapy is a viable treatment option for the latter-line treatment of advanced colorectal cancer, and its safety is well tolerated with sustained benefit
to patients.
Figure 6 Dr.
Tim Song sharing a case
Case 5: Fruquintinib monotherapy to help "chemotherapy" leave The case was provided by the Affiliated East Hospital of Tongji University: Professor Gao Yong; Case Sharer: Dr.
Hai Yanan Case Summary:
The patient is a 64-year-old woman with no special
past or family history.
In 2015, radical rectal cancer was performed, and the pathological detection was low-moderately differentiated carcinoma, and liver and lung metastases occurred successively after surgery, and in 2018, he received bevacizumab + FOLFIRI treatment in the first-line treatment until the disease progressed
in July 2019.
Second-line treatment strategies to prolong survival and improve quality of life, so he began treatment with fruquintinib (5 mg) in July 2019, and disease progression (SD-slow PD)
in August 2020.
In September 2020, he entered palliative third-line treatment, using bevacizumab + FOLFOX, the disease was stable after 13 cycles, and in October 2021, liver and lung metastases
.
Subsequent treatment with bevacizumab + FOLFIRI, liver and lung metastases decreased during treatment, liver PD in June 2022, and lung PD
in July 2022.
Received the PD-1 inhibitor sindilimab + fruquintinib (5 mg) in August 2022 and the patient is currently on
ongoing treatment.
This case suggests that fruquintinib monotherapy can help patients take a "chemotherapy vacation" and better receive back-line treatment
.
Figure 7 Dr.
Hai Yanan sharing a case
Case 6: Young patients are more suitable for fruquintinib combined with PD-1 inhibitorsThe case is provided by the First Affiliated Hospital of Xiamen University: Professor Li Jiayi; Case sharer: Dr.
He Qi Case Summary:
The patient, a 34-year-old woman with repeated mucus discharge for 6 months, dry cough and low back pain for 2 weeks, was diagnosed with stage IV differentiated adenocarcinoma (cT4N+M1b) in the right half (ascending colon) with lung metastasis
.
After MDT discussion, the first-line treatment was bevacizumab combined with XELOX, and the efficacy was evaluated as PR after 6 cycles of treatment, but the primary lesion still had dysfunction, affecting the quality of life of patients, so he underwent right colonectomy in October 2019 and continued XELOX treatment
after surgery.
XELODA maintenance treatment began in December 2019, and his work life is normal
.
In December 2020, a new lesion appeared, and he was treated with mXELIRI, and the disease stabilized after 3 cycles, followed by the introduction of radiotherapy
.
After 8 months of chemoradiotherapy, the disease progresses and third-line therapy
is initiated.
The patient received PD-1 inhibitor combined with fruquintinib (5mg) with no obvious adverse reactions, and the efficacy was evaluated as SD
for 7 months.
Later, it was changed to oral fruquintinib 3mg treatment (unable to be admitted to hospital for injection of sindilimab due to the epidemic).
The disease was stable after 12 months of third-line therapy, and the patient was currently receiving sindilimab + fruquintinib (3 mg), and the PFS was still not achieved
.
This case suggests that for the back-line treatment of young colorectal cancer patients, fruquintinib combined with PD-1 inhibitors has good efficacy and safety, and has a very rich space for
exploration.
Figure 8 Dr.
He Qi made a case report
Through wonderful case sharing, the six doctors fully demonstrated their personal demeanor and the thinking and choices
of the diagnosis and treatment team in the treatment of the above-mentioned real-world cases.
In the end, after the jury judges, Dr.
Hai Yanan from the Dongfang Hospital affiliated to Tongji University performed well and won the excellent case
.
summary
At the end of the meeting, the chairman of the conference made a wonderful summary of the meeting, saying that the six teams presented a very wonderful report, and the doctors reported that the logical thinking was clear and the slide was beautifully
made.
Although it was an online meeting and it was impossible to see the typhoons of the doctors, when reporting the case, the doctors not only presented sufficient evidence-based medical evidence, but also considered the individualization of the treatment process, which showed the solid basic skills of the doctors and the careful preparation
for the presentation.
At the same time, the supplement and guidance of the mentors also have a positive effect
on the growth of young doctors.
It is hoped that through the exchange and learning of this conference, the clinical ability of young doctors will be improved, and more patients with advanced colorectal cancer will
eventually benefit.
